Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

[1]  G. Criner,et al.  Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. , 2015, Immunity.

[2]  C. Brightling,et al.  IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk , 2015, Allergy.

[3]  Yutong Zhao,et al.  Focal Adhesion Kinase–Mediated Activation of Glycogen Synthase Kinase 3β Regulates IL-33 Receptor Internalization and IL-33 Signaling , 2015, The Journal of Immunology.

[4]  N. Papadopoulos,et al.  IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. , 2014, American journal of respiratory and critical care medicine.

[5]  S. Akthar,et al.  Alternaria-derived serine protease activity drives IL-33–mediated asthma exacerbations , 2014, The Journal of allergy and clinical immunology.

[6]  S. Ozen,et al.  A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin , 2014, Nature Reviews Rheumatology.

[7]  Richard T. Lee,et al.  Interleukin 33 as a mechanically responsive cytokine secreted by living cells , 2014 .

[8]  C. Garlanda,et al.  The interleukin-1 family: back to the future. , 2013, Immunity.

[9]  A. Bush,et al.  IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. , 2013, The Journal of allergy and clinical immunology.

[10]  J. Tainer,et al.  Structural insights into the interaction of IL-33 with its receptors , 2013, Proceedings of the National Academy of Sciences.

[11]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[12]  G. Koppelman,et al.  Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. , 2013, The Journal of allergy and clinical immunology.

[13]  K. Ishii,et al.  A critical role of IL-33 in experimental allergic rhinitis. , 2012, The Journal of allergy and clinical immunology.

[14]  Bill B. Chen,et al.  F-box protein FBXL19–mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation , 2012, Nature Immunology.

[15]  P. Mercier,et al.  Endogenous IL-33 Is Highly Expressed in Mouse Epithelial Barrier Tissues, Lymphoid Organs, Brain, Embryos, and Inflamed Tissues: In Situ Analysis Using a Novel Il-33–LacZ Gene Trap Reporter Strain , 2012, The Journal of Immunology.

[16]  B. Monsarrat,et al.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G , 2012, Proceedings of the National Academy of Sciences.

[17]  The Danger Signal, Extracellular ATP, Is a Sensor for an Airborne Allergen and Triggers IL-33 Release and Innate Th2-Type Responses , 2011, The Journal of Immunology.

[18]  K. Yanaba,et al.  Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis , 2011, Clinical Rheumatology.

[19]  Q. Hamid,et al.  Increased IL-33 expression by epithelial cells in bronchial asthma. , 2010, The Journal of allergy and clinical immunology.

[20]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.

[21]  M. Hayakawa,et al.  Increased Levels of Interleukin 33 in Sera and Synovial Fluid from Patients with Active Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[22]  Qutayba Hamid,et al.  Increased Expression of IL-33 in Severe Asthma: Evidence of Expression by Airway Smooth Muscle Cells1 , 2009, The Journal of Immunology.

[23]  Andreas Lingel,et al.  Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. , 2009, Structure.

[24]  Virgil L. Woods,et al.  Pro-interleukin (IL)-1beta shares a core region of stability as compared with mature IL-1beta while maintaining a distinctly different configurational landscape: a comparative hydrogen/deuterium exchange mass spectrometry study. , 2009, The Journal of biological chemistry.

[25]  S. Cullen,et al.  Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. , 2009, Immunity.

[26]  J. Girard,et al.  The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 , 2009, Proceedings of the National Academy of Sciences.

[27]  J. Girard,et al.  The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’? , 2008, PloS one.

[28]  H. Hoffmann,et al.  Comparison of short term in vitro cultured human mast cells from different progenitors - Peripheral blood-derived progenitors generate highly mature and functional mast cells. , 2008, Journal of immunological methods.

[29]  Dirk E. Smith,et al.  The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. , 2008, Cytokine.

[30]  M. Huber,et al.  IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells , 2007, Proceedings of the National Academy of Sciences.

[31]  R. Kastelein,et al.  IL-1 Receptor Accessory Protein and ST2 Comprise the IL-33 Receptor Complex , 2007, The Journal of Immunology.

[32]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[33]  N. C. Price,et al.  How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.

[34]  Paul Schanda,et al.  Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. , 2005, Journal of the American Chemical Society.

[35]  N. Kondo,et al.  Generation of highly stable IL-18 based on a ligand-receptor complex structure. , 2004, Biochemical and biophysical research communications.

[36]  Scott Carver,et al.  Cytokine traps: multi-component, high-affinity blockers of cytokine action , 2003, Nature Medicine.

[37]  Larry L. Constantine,et al.  Back to the future , 2001, CACM.

[38]  T. Arakawa,et al.  Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. , 1996, Biophysical journal.

[39]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[40]  D. Hazuda,et al.  Purification and characterization of human recombinant precursor interleukin 1 beta. , 1989, The Journal of biological chemistry.

[41]  P. Young,et al.  Purification and characterization of human recombinant interleukin-1 beta. , 1987, The Journal of biological chemistry.

[42]  P. Wingfield,et al.  Conformation, stability, and folding of interleukin 1 beta. , 1987, Biochemistry.

[43]  S. Moore,et al.  THE CONCENTRATIONS OF CYSTEINE AND CYSTINE IN HUMAN BLOOD PLASMA. , 1960, The Journal of clinical investigation.